Interestingly, the beneficial advantage of either CD5-CARs or the CAR-NK framework was not observed in peripheral T-cell lymphoma patient samples and T cells in vitro, and all constructs were similarly effective. The gene discussed is CD5; the disease is T-cell non-Hodgkin lymphoma.